Tessa’s TT11X utilizes CD30.CAR-modified Allogeneic Epstein-Barr Virus Specific T-Cell (EBVST) to people relapsed oregon refractory CD30-positive lymphomas
Exploring indications for coagulated tumors, expanding the imaginable for CAR-T
SINGAPORE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage compartment therapy institution processing next-generation crab treatments for hematological malignancies and coagulated tumors, contiguous announced the execution of an exclusive statement with Baylor College of Medicine for worldwide commercialized rights to the allogeneic Epstein-Barr microorganism circumstantial T-cell (EBVST) exertion level developed jointly by Tessa’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and his colleagues Cliona Rooney Ph.D. and Helen Heslop M.D., D.Sc. astatine Baylor College of Medicine. Tessa is presently advancing a pipeline of products that utilize CD30.CAR-modified EBVSTs, including its pb allogeneic compartment therapy, TT11X, which is being co-developed for the attraction of relapsed oregon refractory CD30-positive lymphomas.
CD30.ALLO Virus circumstantial T-cells (VSTs) are highly specialized T cells that tin admit CD30+ tumors. CD30 Allogeneic VSTs without familial modification person demonstrated a beardown information illustration and efficacy successful aboriginal trials with minimal hazard of Graft vs Host Disease (GVHD). During the improvement of the allogeneic exertion platform, Tessa and Baylor College of Medicine had an exclusive enactment statement for commercialized rights to the technology.
Clinical information from an ongoing Phase 1 survey of TT11X successful CD30-positive lymphomas (BESTA) has demonstrated a favorable information illustration and encouraging signs of efficacy with objective responses observed successful 7 of 9 patients, including a implicit disappearance of tumors reported successful 4 patients. TT11X was precocious recognized successful the “Most Promising Off-the-Shelf Therapies” class astatine the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022.
“Allogeneic oregon ‘off-the-shelf’ CAR-T therapies person the imaginable to alteration the paradigm of crab treatment, and we judge the allogeneic EBVST level developed astatine the Center for Cell and Gene Therapy, astatine Baylor College of Medicine places Tessa astatine the forefront of a precise important therapeutic and concern opportunity,” said Thomas Willemsen, Tessa’s President and Chief Executive Officer. “Securing exclusive worldwide commercialized rights for therapies developed utilizing the EBVST level is an important worth operator for Tessa arsenic we proceed to beforehand TT11X arsenic a imaginable attraction for CD30-positive lymphomas, portion exploring opportunities to widen the exertion to different crab indications, including coagulated tumors.”
About Tessa Therapeutics
Tessa Therapeutics is simply a clinical-stage biotechnology institution processing next-generation compartment therapies for the attraction of hematological cancers and coagulated tumors. Tessa’s pb objective asset, TT11, is an autologous CD30-CAR-T therapy presently being investigated arsenic a imaginable attraction for relapsed oregon refractory classical Hodgkin lymphoma arsenic some a monotherapy (Phase 2) and operation therapy (Phase 1b). TT11 has been granted RMAT designation by the FDA and entree to the PRIME strategy by European Medicine Agency. Tessa is besides advancing an allogeneic “off-the- shelf” compartment therapy level targeting a wide scope of cancers successful which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy utilizing this level is presently the taxable of a Phase 1 objective proceedings successful CD30-positive lymphomas. Tessa has its planetary office successful Singapore, wherever the institution has built a authorities of the art, commercialized compartment therapy manufacturing facility. For much accusation connected Tessa, sojourn www.tessacell.com.
Cautionary Note connected Forward Looking Statements
This property merchandise contains forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, to the fullest grade applicable) including, without limitation, with respect to assorted regulatory filings oregon objective survey developments of the Company. You tin place these statements by the information that they usage words specified arsenic “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” oregon akin expressions. Any forward-looking statements successful this property merchandise are based connected management’s existent expectations and beliefs and are taxable to a fig of risks, uncertainties and important factors that whitethorn origin existent events oregon results to disagree materially from those expressed oregon implied by immoderate forward-looking statements contained successful this property release, including, without limitation, those related to the Company’s fiscal results, the quality to rise capital, dependence connected strategical partnerships and licensees, the applicability of patents and proprietary technology, the timing for completion of the objective trials of its merchandise candidates, whether and when, if astatine all, the Company’s merchandise candidates volition person selling approval, and contention from different biopharmaceutical companies. The Company cautions you not to spot undue reliance connected immoderate forward-looking statements, which talk lone arsenic of the day they are made, and disclaims immoderate work to publically update oregon revise immoderate specified statements to bespeak immoderate alteration successful expectations oregon successful events, conditions oregon circumstances connected which immoderate specified statements whitethorn beryllium based, oregon that whitethorn impact the likelihood that existent results volition disagree from those acceptable distant successful the forward-looking statements. Any forward-looking statements contained successful this property merchandise correspond the Company’s views lone arsenic of the day hereof and should not beryllium relied upon arsenic representing its views arsenic of immoderate consequent date. The Company’s products are expressly for investigational usage pursuant to a applicable investigational instrumentality exemption granted by the U.S. Food & Drug Administration, oregon equivalent competent body.
Tessa Therapeutics Investor Contact
Wilson W. Cheung
Chief Financial Officer
wcheung@tessacell.com
Tessa Therapeutics Media Contact
Tiberend Strategic Advisors, Inc.
Bill Borden
+1-732-910-1620
bborden@tiberend.com
Dave Schemelia
+1-609-468-9325
dschemelia@tiberend.com
English (US)